From discovery to
clinical diagnostic development.
Foli Bio is building a portfolio of internal clinical diagnostic pipelines across gut-associated diseases, translating stool-derived host RNA signatures into non-invasive assays for disease monitoring, patient stratification, and precision medicine applications.
Clinical diagnostic programs
Helps identify IBD patients more likely to benefit from anti-TNF therapy before treatment initiation, supporting more informed biologic selection.
Tracks mucosal inflammation and epithelial injury to help assess whether treatment is adequately controlling disease activity when endoscopy is not performed.
Non-invasive screening for colorectal cancer and high-risk precancerous lesions, including advanced adenomas and serrated polyps.
Additional diagnostic programs applying stool-derived host RNA signatures across gut-associated diseases. Partners and program details are not publicly disclosed.
Interested in partnerships or co-development?
We welcome discussions with pharma, biotech, clinical, and academic partners interested in co-developing diagnostic programs or applying Foli-seq™ to translational studies, biomarker discovery, and clinical validation.